Vita Life Sciences Ltd
ASX:VLS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.6
2.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vita Life Sciences Ltd
Relative Value
The Relative Value of one
VLS
stock under the Base Case scenario is
2.14
AUD.
Compared to the current market price of 2.08 AUD,
Vita Life Sciences Ltd
is
Undervalued by 3%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
VLS Competitors Multiples
Vita Life Sciences Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Vita Life Sciences Ltd
ASX:VLS
|
117.3m AUD | 1.5 | 12.5 | 7.3 | 7.3 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
710.5B USD | 17.4 | 84.9 | 45.7 | 51 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.3T DKK | 12.3 | 35 | 24.3 | 27.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.5B USD | 4.3 | 25.4 | 12.3 | 16 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
251.1B USD | 4 | 20.7 | 10.5 | 12.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
202.7B CHF | 3.5 | 17.6 | 9.9 | 11.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
183.3B CHF | 4.1 | 11.7 | 10.1 | 14 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162.4B GBP | 4.1 | 31.6 | 169.4 | 253.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
146B USD | 63 | -49.9 | 234.4 | 587.7 |
You don't have any saved screeners yet
